Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689256 | 0.81 | ERN1 (0.45) | ERN1NPBWR1PTGER2PIN1KMO | |
| SCHEMBL13788157 | 0.79 | EGLN1 (0.46) | EGLN1CNR2 | |
| SCHEMBL10215308 | 0.73 | ERN1 (0.47) | ERN1NPBWR1KMOCNR2 | |
| SCHEMBL13944438 | 0.71 | ERN1 (0.45) | ERN1NPBWR1GSK3B | |
| SCHEMBL21200019 | 0.71 | KDM4E (0.52) | EGLN1PIN1CNR2 | |
| SCHEMBL1583795 | 0.67 | ERN1 (0.43) | ERN1NPBWR1KMO | |
| SCHEMBL3694859 | 0.65 | ERN1 (0.41) | ERN1NPBWR1KMO | |
| SCHEMBL3642233 | 0.65 | ADORA3 (0.53) | EGLN1 | |
| SCHEMBL3685804 | 0.64 | ERN1 (0.40) | ERN1NPBWR1KMO | |
| SCHEMBL1583247 | 0.64 | ERN1 (0.40) | ERN1NPBWR1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | ERN1 237/4885EGLN1 369/4885NPBWR1 3024/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | ERN1 237/4885EGLN1 369/4885NPBWR1 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.